The Inactivation and Catalytic Pathways of Horseradish Peroxidase with m-Chloroperoxybenzoic Acid
A SPECTROPHOTOMETRIC AND TRANSIENT KINETIC STUDY*

(Received for publication, July 30, 1996, and in revised form, October 29, 1996)

Jose Neptuno Rodriguez-Lopez Dagger §, Josefa Hernández-Ruiz par , Francisco Garcia-Cánovas **, Roger N. F. Thorneley Dagger Dagger Dagger , Manuel Acosta and Marino B. Arnao Dagger Dagger

From the Dagger  Nitrogen Fixation Laboratory, John Innes Centre, NR4 7UH Norwich, United Kingdom and the  Departamento de Biología Vegetal (Fisiología Vegetal) and ** Departamento de Bioquímica y Biología Molecular A, Universidad de Murcia, 30100 Murcia, Spain

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
CONCLUSIONS
FOOTNOTES
REFERENCES


ABSTRACT

The kinetics of the catalytic cycle and irreversible inactivation of horseradish peroxidase C (HRP-C) reacting with m-chloroperoxybenzoic acid (mCPBA) have been studied by conventional and stopped-flow spectrophotometry. mCPBA oxidized HRP-C to compound I with a second order-rate constant k1 = 3.6 × 107 M-1 s-1 at pH 7.0, 25 °C. Excess mCPBA subsequently acted as a one-electron reducing substrate, converting compound I to compound II and compound II to resting, ferric enzyme. In both of these reactions, spectrally distinct, transient forms of the enzyme were observed (lambda max = 411 nm, epsilon  = 45 mM-1 cm-1 for compound I with mCPBA, and lambda max = 408 nm, epsilon  = 77 mM-1 cm-1 for compound II with mCPBA). The compound I-mCPBA intermediate (shown by near infrared spectroscopy to be identical to P965) decayed either to compound II in a catalytic cycle (k3 = 6.4 × 10-3 s-1) or, in a competing inactivation reaction, to verdohemoprotein (ki = 3.3 × 10-3 s-1). Thus, a partition ratio of r = 2 is obtained for the inactivation of ferric HRP-C by mCPBA. The intermediate formed from compound II with mCPBA is not part of the inactivation pathway and only decays via the catalytic cycle to give resting, ferric enzyme (k5 = 1.0 × 10-3 s-1). The data are compared with those from earlier steady-state kinetic studies and demonstrate the importance of single turnover experiments. The results are discussed in terms of the physiologically relevant reactions of plant peroxidases with hydrogen peroxide.


INTRODUCTION

Horseradish peroxidase (HRP)1 (donor:hydrogen peroxide oxidoreductase, EC 1.11.1.7) is an extracellular plant enzyme involved in the formation of free radical intermediates for the polymerization and cross-linking of cell wall components, for the oxidation of secondary metabolites essential for certain pathogenic defense reactions, and for the regulation of cell growth and differentiation (1). There are more than 30 isoforms of HRP, which are usually classified, according to isoelectric point, into three major groups: acidic, neutral, and basic (2). The slightly basic (cationic) horseradish peroxidase C (HRP-C) is the most studied isoform, since it constitutes approximately 50% of the peroxidase content of horseradish root and is commercially available because of its use in clinical analysis and biotransformations (see Refs. 3-5 for reviews of its structure and function).

HRP-C is a monomeric (Mr of 33,922), glycosylated (18% by mass) enzyme that contains a single high spin ferric protoporphyrin IX prosthetic group and two calcium ions (6-8) that are necessary for competent folding of the recombinant enzyme after expression in Escherichia coli (9). The catalytic cycle is initiated by a rapid (k1 > 107 M-1 s-1) 2e- oxidation of the enzyme by hydrogen peroxide (or other organic peroxides) to give a green enzyme intermediate, compound I, with the heme iron oxidized to the oxyferryl state (Fe(IV)=O) and a pi -cation radical on the porphyrin ring. Compound I formation involves at least two reactions; formation of an intermediate enzyme-hydroperoxide complex (10), followed by heterolytic cleavage of the oxygen-oxygen bond. Histidine 42 and arginine 38, located in the distal heme cavity, are key residues that modulate both these reactions (11, 12). In order to complete a peroxidation cycle, compound I is reduced back to the resting Fe(III) state by two successive single electron transfer reactions from reducing substrate molecules, the first yielding a second enzyme intermediate, compound II. Both of these reactions can yield free radical products that can undergo subsequent chemistry. The rate of the peroxidation cycle usually depends on the nature of the reducing substrate, with the reduction of compound II to resting enzyme being rate-limiting (3).

In the absence of reducing substrates, excess hydrogen peroxide can react with compound I as an electron donor (reductant) in a catalase-like two-electron process that results in the formation of molecular oxygen or in two single-electron transfers in which compound II, compound III (Fe(II)-O2), and superoxide radical anion (Obardot 2) are formed (13-15). Importantly in the context of this paper, a competing enzyme inactivation takes place that results in the generation of a number of inactive chromophores with the final product being a verdohemoprotein, P670 (16-19). A global reaction scheme that includes all the previously identified partial reactions of the catalytic cycle and the inactivation pathway has been developed using experimentally determined steady-state kinetic parameters for the HRP-C/H2O2 system (20). It was concluded that the catalase-like and compound III generating activities of HRP-C protect against inactivation and that the extent of inactivation is determined by the reactivity of a common intermediate, the complex formed between compound I and a second equivalent of H2O2 (18, 20). Consequently, with excess H2O2 as the only reducing substrate, the enzyme is completely inactivated after only ~600 turnovers (20). A simplified form of the reaction scheme has recently been developed to enable a more rapid, comparative analysis of data for isoenzymes from diverse sources (21) and to determine the effects of selected mutations in recombinant HRP-C (22).

A complementary approach to understanding the inactivation mechanism of HRP-C utilizes the competent, xenobiotic substrate, meta-chloroperoxybenzoic acid (mCPBA) instead of hydrogen peroxide. Compound I formation results in the release of the parent carboxylic acid instead of water (23) (Scheme I). Importantly, HRP-C in the ferric, compound I, and compound II states has a high affinity for mCPBA possibly because of its structural resemblance to reducing organic substrates such as benzhydroxamic acid (24-26) and indole-3-acetic acid (27, 28). These affinities permit single turnover experiments, with an excess of enzyme over substrate, using rapid-scan stopped-flow spectrophotometry. These conditions allow a precise determination of the values of the rate constants for the partial reactions shown in Table I in the absence of subsequent reactions that would occur at significant rates with an excess of mCPBA. In addition, the absence of the catalase-like cycle (13, 26, 29) causes the average number of turnovers effected by each molecule of enzyme before inactivation (r) to drop to very low values, typically 2 or 3 (22, 26, 30). This simplifies the kinetic analysis and aids the identification of intermediates in both the catalytic cycle and on the inactivation pathway, facilitates simulations of the complex absorbance changes, and allows a more rigorous test of our proposed mechanism of inactivation shown in Scheme I than was possible using pseudo-steady-state kinetics. In addition it has allowed us to show unambiguously that the reactivity of the complex formed between compound I and mCPBA is the key intermediate that determines the extent of inactivation. The results with mCPBA validate our earlier conclusions for the reactions of HRP-C with hydrogen peroxide, where it was only possible to use pseudo-steady-state kinetics, and allow us to discuss with greater confidence the physiological implications.


Scheme I. Reaction mechanism of mCPBA with HRP-C. The species are as follows: E, native enzyme; compound I and compound II, active forms of the enzyme; Ei (P-670), inactive form of the enzyme; mCBA, m-chlorobenzoic acid; R·, peroxyl radical of mCPBA.
[View Larger Version of this Image (8K GIF file)]


Table I.

The reaction of mCPBA with native HRP-C, compound I, and compound II


Scheme Reaction

k1         
II E + mCPBA right-arrow CoI
    k2      ki
III CoI + mCPBA right-left-arrows [Col · mCPBA] right-arrow Ei
              k-2down-arrow k3
CoII
k4    k5
IV CoII + mCPBA right-left-arrows [CoII · mCPBA] right-arrow E
k-4


MATERIALS AND METHODS

Reagents

Horseradish peroxidase isoenzyme C was purchased from Biozyme (Type HRP-4B) and used without further purification. Characterization by electrophoresis and isoelectric focusing (21) revealed a band for peroxidase activity at pI 8.5, typical of a basic isoenzyme. Its concentration was determined spectrophotometrically using epsilon 403 nm = 102 mM-1 cm-1. A specific activity of 1,322 µmol mg-1 min-1 was determined using 0.2 mM H2O2 and 0.5 mM ABTS as the reducing substrate in 50 mM glycine-HCl buffer, pH 4.5 at 25 °C. The preparations used for this study had ratios of absorbance at 403/280 nm (RZ value) of 3.2. mCPBA in the solid state (Aldrich) containing m-chlorobenzoic acid as an impurity was recrystallized from light petroleum ether (boiling point 40-60 °C)/diethylether (3:1, v/v) as described by Davies et al. (24), to give material that was more than 96% pure (NMR analysis and single melting point at 92-94 °C). Solutions of mCPBA were made up in 1:1 (v/v) absolute ethanol/water immediately prior to use. The concentration was determined using epsilon 232 nm = 8,940 M-1 cm-1 allowing for the percentage purity obtained by NMR (26). Reagent grade H2O2 (30% v/v) was obtained from BDH, and its concentration determined spectrophotometrically using an epsilon 240 nm of 43.6 M-1 cm-1 (31). ABTS was supplied by Sigma as a diammonium salt, and solution concentrations were determined using a epsilon 340 nm of 36 mM-1 cm-1 (32).

Equipment

Transient kinetics were monitored with a stopped-flow spectrophotometer (model SF-51), Hi-Tech Scientific, Salisbury, United Kingdom. Data were recorded through an RS232 interface with a microcomputer. Stopped-flow rapid-scan spectrophotometry was carried out with the same sample handling unit equipped with an MG-6000 diode array system. Spectrophotometric measurements were made with a Perkin-Elmer Lambda-2 UV-visible spectrophotometer controlled by an Olivetti PCS/386SX computer running dedicated software. The temperature was controlled at 25 or 10 °C using a Techne C-400 circulating bath with an integral heater-cooler system.

Pre-steady-state Kinetics

Compound I formation was monitored at 395 nm (isosbestic for compounds I and II). Compound II formation from compound I was monitored at 412 nm (isosbestic for compound II and the resting enzyme). Compound I was generated by mixing enzyme with an equimolecular amount of H2O2 in a simple pre-mixing device attached to one of the transport syringe ports on the stopped-flow apparatus and transferred directly to a drive syringe for use within 5 min of preparation. Compound II was made from compound I (prepared as described above) by oxidative titration with ascorbic acid. The disappearance of compound II was monitored at 424 nm (the isosbestic for compound I and the ferric enzyme). The formation of verdohemoprotein was followed at 670 nm. The determination of the reaction rates were carried out under single turnover conditions with [E]0 > [S]0 (33). Pre-steady-state kinetic experiments were performed in 10 mM sodium phosphate buffer, pH 7.0, and the data analyzed by fitting the absorbance-time curves to exponential functions using a least-squares minimization procedure.

Spectrophotometry

The detection of enzyme intermediates and final products from reactions of ferric enzyme, compound I or compound II were carried out by mixing these species with a stoichiometric amount of mCPBA. Transient and final spectra were deconvoluted using a SPECFIT Global Analysis computer program (Spectrum Software Associates, Chapel Hill, NC). All experiments were in 10 mM sodium phosphate buffer, pH 7.0.

Kinetic Simulations

The kinetics of the reaction mechanism described in Scheme I is defined by a set of differential equations, whose numerical integration was carried out using a KSIM computer program provided by Dr. N. Millar. The differential equations are shown in Equations 1-6 below.
[E]=k<SUB>5</SUB>[<UP>compound II-mCPBA</UP>]−k<SUB>1</SUB>[E][<UP>mCPBA</UP>] (Eq. 1)
[<UP>compoundI</UP>]=k<SUB>1</SUB>[E][<UP>mCPBA</UP>]+k<SUB>−2</SUB>[<UP>compound I-mCPBA</UP>]−k<SUB>2</SUB>[<UP>compound I</UP>] (Eq. 2)
[<UP>compound I-mCPBA</UP>]=k<SUB>2</SUB>[<UP>compound I</UP>][<UP>mCPBA</UP>]−(k<SUB>−2</SUB>+k<SUB>3</SUB>+k<SUB>i</SUB>)[<UP>compound I-mCPBA</UP>] (Eq. 3)
[E<SUB>i</SUB>]=k<SUB>i</SUB>[<UP>compound I-mCPBA</UP>] (Eq. 4)
[<UP>compound II</UP>]=k<SUB>3</SUB>[<UP>compound I-mCPBA</UP>]+k<SUB>−4</SUB>[<UP>compound II-mCPBA</UP>]−k<SUB>4</SUB>[<UP>compound II</UP>][<UP>mCPBA</UP>] (Eq. 5)
[<UP>compound II-mCPBA</UP>]=k<SUB>4</SUB>[<UP>compound II</UP>][<UP>mCPBA</UP>]−(k<SUB>−4</SUB>+k<SUB>5</SUB>)[<UP>compound II-mCPBA</UP>] (Eq. 6)

Experimentally determined values of the equilibrium and rate constants were assigned to the partial reactions defined in Scheme I. The kinetics of the intermediates and products defined in Schemes II, III, and IV (shown in Table I) were simulated using the corresponding differential equations.


RESULTS AND DISCUSSION

The Inactivation Pathway of HRP

Formation of verdohemoprotein (P670), with its characteristic absorption maximum at 670 nm, is diagnostic of peroxidase inactivation (19). The titration data shown in Fig. 1 with both spectrophotometric and enzyme activity monitoring show that at least two equivalents of mCPBA were required for its formation starting from HRP-C in the ferric state (Fig. 1). The loss of enzymatic activity is clearly proportional to the extent of P670 formation. These findings are consistent with the first equivalent mCPBA being used to form compound I and the second to inactivate the enzyme and suggest that compound I is a common intermediate in the catalytic cycle and at the beginning of the inactivation pathway (Scheme III shown in Table I). It can also be calculated from Fig. 1 that 8 mol of mCPBA are needed to completely inactivate 1 mol of enzyme ([substrate]/[enzyme] ratio = 70 µM/8.7 µM = 8.0). These equivalents are distributed between the catalytic cycle and the inactivation pathway (Scheme I).


Fig. 1. Stoichiometry of the reaction between HRP-C and mCPBA. The increase in absorbance at 670 nm is the maximum value reached in the reaction of 8.7 µM HRP-C with varying amounts of mCPBA in 10 mM sodium-phosphate buffer (pH 7.0), 25 °C. The residual enzyme activity was determined using the ABTS oxidation assay.
[View Larger Version of this Image (21K GIF file)]


Compound I Formation

The reaction of HRP-C with a stoichiometric concentration of mCPBA yielded compound I with a UV-visible spectrum that was identical to that described for the reaction of this enzyme with hydrogen peroxide (23). No differences in the stability of this compound I were observed when compared with the compound I formed with hydrogen peroxide under the same conditions. The kinetics of the reaction of HRP-C with mCPBA to form compound I have been shown by Dunford and Hewson (34) to have a viscosity dependence characteristic of a diffusion limited reaction (k1 = 8.2 × 107 M-1 s-1 independent of pH in the range 5.0-6.8). Under single turnover conditions ([HRP-C]0 > [mCPBA]0) (Fig. 2), we have determined that k1 = (3.6 ± 0.6) × 107 M-1 s-1 at pH 7.0 (Table I). Under these conditions, no inactivation of the enzyme occurred nor was any verdohemoprotein formed.


Fig. 2. Linear plot of the second-order rate constant, kobs, versus HRP-C concentration for the reaction of native enzyme with 0.5 µM mCPBA under single turnover conditions in 10 mM sodium-phosphate buffer (pH 7.0), 25 °C.
[View Larger Version of this Image (15K GIF file)]


The Reaction of mCPBA with Compound I

The two competing reactions that the complex formed between compound I and mCPBA undergoes (Scheme III shown in Table I) are proposed to explain the relationship between catalytic cycle and the inactivation pathways. In order to detect this transient intermediate and to determine the kinetics and mechanism of its formation and decay, the reaction of compound I with mCPBA was studied under stoichiometric conditions. Fig. 3A shows the formation of compound I-mCPBA intermediate and its subsequent decay to compound II and P670. The spectrum of the compound I-mCPBA complex was recorded after a 1-s reaction time and showed maxima at 411, 531, 556, and 649 nm and a shoulder at 615 nm (Fig. 3B). The extinction coefficient in the Soret region was calculated to be 45 mM-1 cm-1 using a global analysis with the computer program SPECFIT. A similar spectrum to that assigned to the compound I-mCPBA complex (Fig. 3B) was obtained in the reaction of compound I with m-chlorobenzoic acid, the parent carboxylic acid (not-peroxo form) of mCPBA (Fig. 4). This reaction when followed at 405 nm showed monophasic kinetics with a second-order rate constant of 5.3 × 103 M-1 s-1 and a dissociation constant of 0.25 mM. These results indicate that the complex formed between compound I and mCPBA is a real enzyme-substrate complex and could serve as a model for the HRP-C compound I-reducing substrate complex, which cannot be detected with conventional reducing substrates such as guaiacol or ABTS.


Fig. 3. The reaction of compound I (10 µM) with mCPBA (10 µM) in 10 mM sodium-phosphate buffer (pH 7.0), 25 °C. Panel A, rapid-scan stopped-flow data with the first scan taken 4.4 ms after mixing. The subsequent scans were at 34-s intervals. Panel B, rapid-scan spectra recorded 1 s after the mixing. The arrows show the direction of absorbance change with time.
[View Larger Version of this Image (20K GIF file)]



Fig. 4. Spectrum of the reaction of HRP-C compound I (10 µM) with m-chlorobenzoic acid (1 mM) in 10 mM sodium-phosphate buffer (pH 7.0), 25 °C.
[View Larger Version of this Image (15K GIF file)]


The enzyme species designated P940 and P670 have been observed previously in the reaction of HRP-C with an excess of hydrogen peroxide (19) and other peroxides (16-18). Another species, P965, has also been observed in the reaction of HRP-C with m-nitroperoxybenzoic acid (18). These authors proposed a sequential mechanism in which P965, formed directly from the reaction of compound I with m-nitroperoxybenzoic acid, subsequently reacted irreversibly with a second equivalent of the peroxide to give initially form P940 and then finally P670. In order to clarify the number of enzyme intermediates in the inactivation pathway, we have studied the reaction of compound I with mCPBA in the near infrared region (Fig. 5). We have been restricted to using conventional spectrophotometry with the first observation after manual mixing at ~15 s since our stopped-flow apparatus has a long wavelength limit of 700 nm. During the course of the reaction, an isosbestic point is maintained at 735 nm. The kinetics of the decrease in absorbance at 965 nm and the increase at 670 nm were identical and were fitted to a single exponential function with kobs = 4 × 10-3 s-1 at 10 °C, independent of the concentration of mCPBA (Fig. 5, inset). At the beginning, an increase in absorbance at 965 nm took place as consequence of the compound I-mCPBA complex formation. These data strongly suggest that the compound I-mCPBA complex is P965, which is the only intermediate that is detected when compound I is converted to verdohemoprotein (P670) by reaction with one equivalent of mCPBA. The similarity in the spectra of the complexes formed between compound I and both mCPBA and m-chlorobenzoic acid (Figs. 3B and 4, respectively) points to a chemical nature of P965 related to an unreacted enzyme-substrate intermediate whose formation is reversible, as was previously suggested for the (compound I-m-nitroperoxybenzoic acid) complex (18). The subsequent chemical structural change probably take place later, during the transition P965 right-arrow P670.


Fig. 5. The reaction of native HRP-C (10 µM) with mCPBA (20 µM) in 10 mM sodium-phosphate buffer (pH 7.0), 10 °C. Spectral changes (curves a-e) are scans of 15 s, 1, 3, 4, and 5 min, respectively, initiated at the start of the mixing. The arrows show the direction of spectral changes with time. Inset, time courses at 670 and 965 nm.
[View Larger Version of this Image (32K GIF file)]


However, not all of the P965 is converted to P670 due to the competing decay reaction that yields compound II (Scheme III shown in Table I). Under single turnover conditions, with the first step equilibrating rapidly (k2[mCPBA] + k-2 >>  k3, ki), the relaxation times are given by Equations 7 and 8.
&lgr;<SUB>1</SUB>=k<SUB>2</SUB>[<UP>compound I</UP>]+k<SUB>−2</SUB> (Eq. 7)
&lgr;<SUB>2</SUB>=&lgr;<SUP><UP>max</UP></SUP><SUB>2</SUB>[<UP>compound I</UP>]/(K<SUB>2</SUB>+[<UP>compound I</UP>]) (Eq. 8)
K2 is the dissociation constant of the complex formed between compound I and mCPBA into compound I (K2 = k-2/k2) and lambda 2max = (k3 + ki). Equations 7 and 8 show that the faster relaxation time, lambda 1, corresponds to the formation of the compound I-mCPBA complex and is independent of the slower process. However, the slower relaxation time, lambda 2, is affected by the fast process (35). Under pseudo-first order conditions, with the concentration of compound I in large excess, the observed first-order rate constant for the formation of compound I-mCPBA at 411 nm exhibited a linear dependence with the concentration of compound I (Fig. 6). These data, together with Equation 7, allow the values of the elementary rate constant (k2 and k-2) and the dissociation constant (K2) to be calculated (Table II). The formation of both compound II and verdohemoprotein were followed at 412 and 670 nm, respectively, under single turnover conditions (Fig. 7). Both species were formed with the same observed first-order rate constant, which was independent of the initial concentration of compound I, although the values of the actual first-order rate constants, k3 and ki, differ by a factor of 2 (see below). This surprising feature of the kinetics is predicted by the analysis given in the Appendix section and was confirmed by a series of simulations with different initial conditions, an example of which is shown in Fig. 7 (inset). The observed first-order rate constant is equal to (k3 + ki) and has a value of 10-2 s-1. Note that this last value is similar to that obtained from Fig. 5B, because the process studied is the same, although at different temperature. The value of K2 = 4.5 × 10-6 M is significantly lower than the initial concentration of compound I and therefore lambda 2 = lambda 2max.


Fig. 6. Linear plot of the second-order rate constant, kobs, versus the initial concentration of compound I for the reaction with 0.5 µM mCPBA under single turnover conditions in 10 mM sodium-phosphate buffer (pH 7.0), 25 °C.
[View Larger Version of this Image (15K GIF file)]


Table II.

Kinetic constants which characterized the inactivation of HRP-C by mCPBA


Catalytic step Pre-steady-statea Pseudo-steady-stateb

E + mCPBA right-arrow CoI k1 (M-1s-1) = (3.6 ± 0.6) × 107
CoI + mCPBA right-arrow [CoI-mCPBA] k2 (M-1s-1) = (1.1 ± 0.1) × 106
k-2 (s-1) = (4.9 ± 0.1)
K2 (M) = (4.5 ± 0.5) × 10-6 K2 (M) = (6.5 ± 0.2) × 10-6
[CoI-mCPBA] right-arrow CoII k3 (s-1) = (6.4 ± 0.1) × 10-3 k3 (s-1) = (1.0 ± 0.1) × 10-2
[CoI-mCPBA] right-arrow Ei (P-670) ki (s-1) = (3.3 ± 0.1) × 10-3 ki (s-1) = (4.8 ± 0.4) × 10-3
CoII + mCPBA right-arrow [CoII-mCPBA] k4 (M-1s-1) = (3.5 ± 0.1) × 105
k-4 (s-1) = (2.2 ± 0.2) × 10-1
K4 (M) = (5.7 ± 0.5) × 10-7
[CoII-mCPBA] right-arrow E k5 (s-1) = (1.0 ± 0.1) × 10-3 k5 (s-1) = (1.5 ± 0.1) × 10-3
Partition ratio (r) k3/ki = (2.0 ±0.1) k3/ki = (1.8 ± 0.1)

a  This work.
b  Ref. 26.


Fig. 7. Kinetics of P670 and compound II formation. Experimental time courses for the accumulation of P670 (a) and compound II (b) during the reaction of compound I (60 µM) with mCPBA (25 µM) in 10 mM sodium-phosphate buffer (pH 7.0), 25 °C. Inset, simulations of the enzyme species formed in the reaction of compound I (40 µM) with mCPBA (4.0 µM) assuming Scheme III shown in Table I. The following rate constants were used: k2 = 2 × 106 M-1 s-1, k-2 = 3 s-1, k3 = 0.05 s-1, and ki = 0.025 s-1. The time courses for both P670 and compound II exhibited monophasic kinetics with the same observed rate constant of ~0.075 s-1.
[View Larger Version of this Image (21K GIF file)]


In order to determine the individual values of k3 and ki, we have measured the relative amounts of compound II and P670 formed under single turnover conditions as a function of increasing concentration of mCPBA (Fig. 8). The final concentration P670 was determined directly from the increase in absorbance at 670 nm using a calculated epsilon 670 nm = (19.6 ± 2.0) mM-1 cm-1. The final concentration of compound II could not be measured spectrophotometrically since several forms of the enzyme absorb in the Soret region. Instead, it was estimated from the remaining enzymatic activity, using the ABTS oxidation assay. The data in Fig. 8 show that both determinations give a good linear correlation, indicating that the distribution of compound I-mCPBA into compound II (67 ± 3)% and P670 (33 ± 2)% was independent of the initial concentration of the complex. This distribution can be defined as the partition ratio (r = k3/ki = 2.0) and allows the values of k3 and ki to be calculated in good agreement with the values obtained previously under pseudo-steady-state conditions (Table II) (26). In addition, our titration data (Fig. 1) show that 8 mol of mCPBA were necessary to completely inactivate 1 mol of enzyme. According to the calculated partition ratio of 2, the reaction mechanism depicted in Scheme I is consistent with this stoichiometry. Additional consumption of mCPBA in the inactivation pathway would result in a different titration value. In consequence, only one molecule of mCPBA is required to react with compound I for some inactivation to be observed, and this is not consistent with other mechanisms suggesting that two molecules of hydroperoxide from compound I are needed in order to convert the enzyme to inactive P670 state (18).


Fig. 8. Determination of the partition ratio between the catalytic and inactivation pathways of HRP-C. Accumulation of P670 (bullet ) was determined by the increase in absorbance at 670 nm. Compound II accumulation (black-square) was determined by the ABTS assay.
[View Larger Version of this Image (16K GIF file)]


The Reaction of mCPBA with Compound II

An inactivation pathway originating with compound II has been proposed previously (19). In order to further investigate this proposal, we have studied the reaction of compound II with stoichiometric and excess concentrations of mCPBA using conventional diode-array and stopped-flow spectrophotometry. Compound II with characteristic absorption maxima at 417, 529, and 556 nm was generated from compound I by the addition of one equivalent of ascorbic acid. When compound II reacted with one equivalent of mCPBA, a transient spectrum of an intermediate (assumed to be the compound II-mCPBA complex) was initially observed. This spectrum subsequently converted to that characteristic of the native ferric state with an isosbestic point maintained at 411 nm (Fig. 9). The failure to detect any P670 product strongly suggests that only compound I and not compound II is involved in the initiation of the inactivation reaction. Under these conditions and with a 10-fold excess of mCPBA, no spectroscopic evidence for transient compound III formation was obtained. Thus the ferric enzyme product is probably formed by single electron transfer from mCPBA to compound II.


Fig. 9. The reaction of compound II (6.5 µM) with mCPBA (6.5 µM) in 10 mM sodium phosphate buffer (pH 7.0), at 25 °C. Spectrum a corresponds to compound II while spectra b-e were recorded at 5, 60, 180, and 480 s, respectively, after the mixing.
[View Larger Version of this Image (18K GIF file)]


The kinetics of the reaction of compound II with mCPBA were studied under single turnover conditions with increasing concentrations of compound II at a fixed substoichiometric concentration of mCPBA. The time dependence of the absorbance change at 403 nm showed an initial decrease with a minimum at 25 s that corresponds to the formation of the transient intermediate, compound II-mCPBA. This was followed by an increase in the absorbance due to the formation of native ferric enzyme. Assuming compound II-mCPBA complex formation occurs as a rapid pre-equilibrium prior to electron transfer, (k4[mCPBA] + k-4 >>  k5), the observed first order rate constants for the two reactions, lambda '1 and lambda '2, are given by Equations 9 and 10 (35).
&lgr;′<SUB>1</SUB>=k<SUB>4</SUB>[<UP>compound II</UP>]+k<SUB>−4</SUB> (Eq. 9)
&lgr;′<SUB>2</SUB>=&lgr;′<SUP><UP>max</UP></SUP><SUB>2</SUB>[<UP>compound II</UP>]/(K<SUB>4</SUB>+[<UP>compound II</UP>]) (Eq. 10)
lambda 2max = k5 and K4 = k-4/k4.

Fig. 10 shows the linear dependence of lambda '1 on the concentration of compound II under pseudo-first-order conditions ([compound II]0 >>  [mCPBA]0). The slope and intercept give the values of k4, k-4, and K4 (Table II). The electron transfer from mCPBA to compound II within the complex was very slow (lambda '2 = 1.0 × 10-3 s-1), as shown by the kinetics of the appearance of native ferric enzyme with monitoring at 403 nm (data not shown). Under these conditions, the low value of K4 = 5.7 × 10-7 M results in lambda '2 being independent of compound II concentration and equal to k5. This value of k5 is in agreement with that obtained under steady-state conditions with ([mCPBA]0 >>  [HRP-C]0) (Table II) (26).


Fig. 10. Linear plot of the second-order rate constant,, kobs, versus the initial concentration of compound II for the reaction with 0.5 µM mCPBA under single turnover conditions in 10 mM sodium-phosphate buffer (pH 7.0), 25 °C.
[View Larger Version of this Image (15K GIF file)]



CONCLUSIONS

The experiments described above have shown conclusively that mCPBA induced inactivation of HRP-C occurs by the mechanism described in Scheme I. The data are not consistent with the mechanism proposed by Marklund (17) nor with the modified mechanism of Nakajima and Yamazaki (18). Our kinetic and titration data clearly demonstrate that only two molecules of mCPBA are necessary to form inactive verdohemoprotein from the native ferric state of HRP-C. In addition, other mechanisms that have invoked an inactivation pathway originating at the compound II state (19, 36) are also not consistent with our data. No inactivation of the heme was observed when mCPBA reacted with an excess of compound II.

(i) The peroxidase inactivation pathway originates at a transient intermediate formed during the reaction of compound I with the hydroperoxide. This intermediate (P965) can be considered to be a model for the binding of reducing substrates to compound I and has spectral similarities to those of a complex formed between m-chlorobenzoic acid and compound I.

(ii) This intermediate decays in competing reactions to give compound II (67%) and an inactive form of HRP-C, P670 (33%) with mCPBA. The product ratio is determined only by the relative values of the inactivation and the catalytic rate constants.

(iii) The active center in different class III peroxidases appears to be well conserved (1), and the role of amino acids such as His-170, His-42, and Arg-38 is well established for HRP-C (11, 37). Apparently, this active center architecture is optimized for compound I formation, although with excess hydroperoxide inactivation occurs. Consequently, mutations in Arg-38 (22) or His-42 (37) make the variants more susceptible to inactivation by hydroperoxides. However, when conventional reducing substrates such as ABTS or guaiacol are present, the extent of inactivation is decreased since the steady-state level of compound I, which reacts with the hydroperoxide to initiate inactivation, is much lower, i.e. reducing substrate protects the enzyme from inactivation by removing compound I (38, 39).

(iv) It is interesting, from a physiological perspective, to point out that HRP-C shows a high affinity for hydroperoxides, shows a high rate of compound I formation, and is active at low concentrations of reducing substrate. However, it is more sensitive to inactivation under these conditions (21). These properties would allow HRP-C to act as an efficient detoxifying system for the elimination of excess hydroperoxide, providing the nature and concentration of reducing substrate ensures a competent rate of compound II reduction to ferric enzyme in the catalytic cycle. The danger of accumulating deleterious free radical could thus be avoided by a coupled process involving HRP reaction products and an antioxidant (i.e. ascorbic acid) (40, 41). However, if there is a perturbation in the cell status toward more oxidative conditions (i.e. the H2O2 burst induced by pathogenesis), then the detoxifying capacity of the enzyme could be surpassed, its susceptibility to inactivation would increase (at higher oxidant/reductant ratios), and the damaging free radical would not be reduced. Chain reactions could also result which can also contribute to cell death in the so-called "hypersensitive response" (42). The effect of H2O2 and mCPBA in vivo have recently been demonstrated by modifications in the patterns of growth and morphogenesis of lupin hypocotyls after application of different concentrations of these hydroperoxides (43).

The use of pre-steady-state kinetics under single turnover conditions has not only confirmed the values of the limited number of combined rate and equilibrium constants that we have previously determined under pseudo-steady-state conditions with mCPBA in large excess (26), but has also allowed the determination of the elementary rate constants for the partial reactions that comprise the mechanism of inactivation. In addition the UV-visible spectrum of the kinetically competent, common intermediate on the catalytic and inactivation pathways has been obtained. On the other hand, the topological similarity between mCPBA and commonly used suicide substrates such as phenylhydrazines (44, 45) and inhibitors like benzhydroxamic acid (24-26) make it a useful probe not only of aromatic substrate binding site(s) but also the heme access channel architecture and distal cavity, since it reacts with ferric enzyme to give compound I. Clearly, the characterization of mutants of HRP-C and naturally occurring isoenzymes such as HRP-A2 using mCPBA will provide not only additional mechanistic information but also valuable insights into the factors that determine the functional stability of peroxidases with commercial potential.


FOOTNOTES

*   This work was supported in part by a grant from the EU Human Capital and Mobility Programme "Peroxidases in Agriculture and the Environment" (Contract ERB CHRX-CT92-00120) and from Comision Interministerial de Ciencia y Tecnologia (Spain) Project ALI95-0487. The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§   Senior research scientist of the EU Human Capital and Mobility Program Network "Peroxidases in Agriculture and the Environment."
par    Recipient of a fellowship from the Ministerio de Educación y Ciencia (Spain).
Dagger Dagger    To whom correspondence should be addressed: Departamento de Biología Vegetal (Fisiología Vegetal), Facultad de Biología, Campus Espinardo, Universidad de Murcia, 30100 Murcia, Spain. Tel.: 34-68-307100; Fax: 34-68-363963; E-mail: marino{at}fcu.um.es.
1    The abbreviations used are: HRP, horseradish peroxidase; HRP-C, horseradish peroxidase isoenzyme C; mCPBA, m-chloroperoxybenzoic acid; ABTS, 2,2'-azinobis-(3-ethylbenzthiazoline-6-sulfonic acid).

APPENDIX

The proposed mechanism for the reaction of compound I with mCPBA is depicted in Scheme III (shown in Table I). This mechanism is a modification of a two-step mechanism (35) in which compound I is stable but mCPBA induces instability of the complex compound I-mCPBA (46). The time-course equations of the concentrations of compound II and inactive enzyme (P670) under single turnover are given for the following expressions.
[<UP>compound II</UP>]=&agr;<SUB>1</SUB>[<UP>compound I</UP>]+<FENCE><FR><NU>&bgr;<SUB>1</SUB></NU><DE>&lgr;<SUB>1</SUB>(&lgr;<SUB>1</SUB>−&lgr;<SUB>2</SUB>)</DE></FR></FENCE>e<SUP>−&lgr;<SUB>1</SUB>t</SUP> (Eq. 1A)
+<FENCE><FR><NU>&bgr;<SUB>1</SUB></NU><DE>&lgr;<SUB>2</SUB>(&lgr;<SUB>2</SUB>−&lgr;<SUB>1</SUB>)</DE></FR></FENCE>e<SUP>−&lgr;<SUB>2</SUB>t</SUP>
[E<SUB>i</SUB>]=&agr;<SUB>2</SUB>[<UP>compound I</UP>]+<FENCE><FR><NU>&bgr;<SUB>2</SUB></NU><DE>&lgr;<SUB>1</SUB>(&lgr;<SUB>1</SUB>−&lgr;<SUB>2</SUB>)</DE></FR></FENCE>e<SUP>−&lgr;<SUB>1</SUB>t</SUP>+<FENCE><FR><NU>&bgr;<SUB>2</SUB></NU><DE>&lgr;<SUB>2</SUB>(&lgr;<SUB>2</SUB>−&lgr;<SUB>1</SUB>)</DE></FR></FENCE>e<SUP>−&lgr;<SUB>2</SUB>t</SUP> (Eq. 2A)
In Equations 1A and 2A, the terms are defined as shown by Equations 3A-6A below.
&agr;<SUB>1</SUB>=k<SUB>3</SUB>/(k<SUB>3</SUB>+k<SUB>i</SUB>) (Eq. 3A)
&agr;<SUB>2</SUB>=k<SUB>i</SUB>/(k<SUB>3</SUB>+k<SUB>i</SUB>) (Eq. 4A)
&bgr;<SUB>1</SUB>=k<SUB>2</SUB>k<SUB>3</SUB>[<UP>compound I</UP>][<UP>mCPBA</UP>] (Eq. 5A)
&bgr;<SUB>2</SUB>=k<SUB>2</SUB>k<SUB>i</SUB>[<UP>compound I</UP>][<UP>mCPBA</UP>] (Eq. 6A)
The values for lambda 1 and lambda 2 are given by Equations 7A and 8A.
&lgr;<SUB>1</SUB>=<FR><NU>1</NU><DE>2</DE></FR><FENCE><LIM><OP>∑</OP></LIM>k+<RAD><RCD><FENCE><LIM><OP>∑</OP></LIM>k</FENCE><SUP>2</SUP>−4&Pgr;k</RCD></RAD></FENCE> (Eq. 7A)
&lgr;<SUB>2</SUB>=<FR><NU>1</NU><DE>2</DE></FR><FENCE><LIM><OP>∑</OP></LIM>k−<RAD><RCD><FENCE><LIM><OP>∑</OP></LIM>k</FENCE><SUP>2</SUP>−4&Pgr;k</RCD></RAD></FENCE> (Eq. 8A)
For Equations 7A and 8A, terms are defined in Equations 9A and 10A.
<LIM><OP>∑</OP></LIM>k≡k<SUB>2</SUB>[<UP>compound I</UP>]+k<SUB>−2</SUB>+k<SUB>3</SUB>+k<SUB>i</SUB> (Eq. 9A)
&Pgr;k≡k<SUB>2</SUB>(k<SUB>3</SUB>+k<SUB>i</SUB>)[<UP>compound I</UP>] (Eq. 10A)
From Equations 7A through 10A, we have the following relationships for the sum and product of the two relaxation times.
&lgr;<SUB>1</SUB>+&lgr;<SUB>2</SUB>=k<SUB>2</SUB>[<UP>compound I</UP>]+k<SUB>−2</SUB>+k<SUB>3</SUB>+k<SUB>i</SUB> (Eq. 11A)
&lgr;<SUB>1</SUB>&lgr;<SUB>2</SUB>=k<SUB>2</SUB>(k<SUB>3</SUB>+k<SUB>i</SUB>)[<UP>compound I</UP>] (Eq. 12A)
We have observed that the bimolecular process is sufficiently faster that both unimolecular process, or, more strictly, the following inequality holds.
k<SUB>2</SUB>[<UP>compound I</UP>]+k<SUB>−2</SUB>&Gtv;k<SUB>3</SUB>,k<SUB>i</SUB> (Eq. 13A)
In this case, the two relaxation times are well separated. The faster process, lambda 1, is given by Equation 14A and corresponds to Equation 7 under "Results and Discussion."
&lgr;<SUB>1</SUB>=k<SUB>2</SUB>[<UP>compound I</UP>]+k<SUB>−2</SUB> (Eq. 14A)
The longer relaxation time or slower process, lambda 2, can be obtained by substituting Equation 14A into Equation 12A, to obtain Equation 15A, as follows.
&lgr;<SUB>2</SUB>=<FR><NU>(k<SUB>3</SUB>+k<SUB>i</SUB>)[<UP>compound I</UP>]</NU><DE>K<SUB>2</SUB>+[<UP>compound I</UP>]</DE></FR> (Eq. 15A)
K2 is the dissociation constant of the complex compound I-mCPBA into compound I and mCPBA (K2 = k-2/k2).

Therefore, the real time courses for compound II and P670 are given by Equations 16A and 17A.
[<UP>compound II</UP>]=&agr;<SUB>1</SUB>[<UP>compound I</UP>](1−e<SUP>−&lgr;<SUB>2</SUB>t</SUP>) (Eq. 16A)
[E<SUB>i</SUB>]=&agr;<SUB>2</SUB>[<UP>compound I</UP>](1−e<SUP>−&lgr;<SUB>2</SUB>t</SUP>) (Eq. 17A)
The experimental traces obtained at 412 and 670 nm with [compound I] >>  K2, which correspond to the accumulation of compound II and verdohemoprotein, respectively, fit to Equations 16A and 17A with the same observed rate constant (k3 + ki).

A similar procedure can be followed to obtain the equation for the reaction between compound II and mCPBA. In this case the first order rate constants are named lambda '1 and lambda '2, respectively (see Equations 9 and 10, under "Results and Discussion").


REFERENCES

  1. Penel, C., Gaspar, T. H., and Greppin, H. (eds) (1992) Plant Peroxidases: 1980-1990, University of Geneva, Geneva, Switzerland
  2. Shannon, L. M., Kay, E., and Lew, J. Y. (1966) J. Biol. Chem. 241, 2166-2172 [Abstract/Free Full Text]
  3. Dunford, H. B., and Stillman, J. S. (1976) Coord. Chem. Rev. 19, 187-251 [CrossRef]
  4. Yamazaki, I., Tamura, M., and Nakajima, R. (1981) Mol. Cell. Biochem. 40, 143-153 [Medline] [Order article via Infotrieve]
  5. Dunford, H. B. (1991) in Peroxidases in Chemistry and Biology (Everse, J., Everse, K. E., and Grisham, M. B., eds), Vol. II, pp. 1-24, CRC Press, Boca Raton, FL
  6. Marañón, M. J. R., and Van Huystee, R. B. (1994) Phytochemistry 37, 1217-1225 [CrossRef]
  7. Shiro, Y., Kurono, M., and Morishima, I. (1986) J. Biol. Chem. 261, 9382-9390 [Abstract/Free Full Text]
  8. Morishima, I., Kurono, M., and Shiro, Y. (1986) J. Biol. Chem. 261, 9391-9399 [Abstract/Free Full Text]
  9. Smith, A. T., Santama, N., Dacey, S., Edwards, M., Bray, R. C., Thorneley, R. N. F., and Burke, J. F. (1990) J. Biol. Chem. 265, 13335-13343 [Abstract/Free Full Text]
  10. Baeck, H. K., and Van Wart, H. E. (1992) J. Am. Chem. Soc. 114, 718-725
  11. Rodriguez-Lopez, J. N., Smith, A. T., and Thorneley, R. N. F. (1996) J. Biol. Chem. 271, 4023-4030 [Abstract/Free Full Text]
  12. Rodriguez-Lopez, J. N., Smith, A. T., and Thorneley, R. N. F. (1996) J. Biol. Inorg. Chem. 1, 136-142 [CrossRef]
  13. Keilin, D., and Hartree, E. F. (1951) Biochem. J. 49, 88-104
  14. Nicholls, P., and Schonbaum, G. R. (1963) in Biochem. J.The Enzymes (Boyer, P. D., Lardy, H., and Myrbach, K., eds), Vol. 8, pp. 47-225, Academic Press, New York
  15. Nakajima, R., and Yamazaki, I. (1987) J. Biol. Chem. 262, 2576-2581 [Abstract/Free Full Text]
  16. Chance, B. (1949) Arch. Biochem. 21, 416-430
  17. Marklund, S. (1973) Arch. Biochem. Biophys. 154, 614-622 [Medline] [Order article via Infotrieve]
  18. Nakajima, R., and Yamazaki, I. (1980) J. Biol. Chem. 255, 2067-2071 [Abstract/Free Full Text]
  19. Bagger, S., and Williams, R. J. P. (1971) Acta Chem Scand. 25, 976-982
  20. Arnao, M. B., Acosta, M., Del Río, J. A., Varón, R., and García-Cánovas, F. (1990) Biochim. Biophys. Acta 1041, 43-47 [Medline] [Order article via Infotrieve]
  21. Hiner, A. N. P., Hernández-Ruíz, J., García-Cánovas, F., Arnao, M. B., and Acosta, M. (1996) Biotech. Bioeng. 50, 655-662 [CrossRef]
  22. Hiner, A. N. P., Hernández-Ruíz, J., García-Cánovas, F., Smith, A. T., Arnao, M. B., and Acosta, M. (1995) Eur. J. Biochem. 234, 506-512 [Abstract]
  23. Schonbaum, G. R., and Lo, S. (1972) J. Biol. Chem. 247, 3353-3360 [Abstract/Free Full Text]
  24. Davies, D. M., Jones, P., and Mantle, D. (1976) Biochem. J. 157, 247-253 [Medline] [Order article via Infotrieve]
  25. Job, D., and Jones, P. (1978) Eur. J. Biochem. 86, 565-572 [Medline] [Order article via Infotrieve]
  26. Arnao, M. B., Hernández-Ruíz, J., Varón, R., García-Cánovas, F., and Acosta, M. (1995) J. Mol. Catal. A Chem. 104, 179-191 [CrossRef]
  27. Acosta, M., Del Río, J. A., Arnao, M. B., Sánchez-Bravo, J., Sabater, F., García-Carmona, F., and García-Cánovas, F. (1988) Biochim. Biophys. Acta 955, 194-202
  28. Gazaryan, I. G., Lagrimini, M., Ashby, G. A., and Thorneley, R. N. F. (1996) Biochem. J. 322, 841-847
  29. Chamulitrat, W., Takahashi, N., and Mason, R. P. (1989) J. Biol. Chem. 264, 7889-7899 [Abstract/Free Full Text]
  30. Acosta, M., Arnao, M. B., Hernández-Ruíz, J., and García-Cánovas, F. (1993) in Plant Peroxidases: Biochemistry and Physiology (Welinder, K. G., Rasmussen, S. K., Penel, C., and Greppin, H., eds), pp. 201-205, University of Geneva, Geneva, Switzerland
  31. Bielski, B. H. D., and Allen, A. O. (1977) J. Phys. Chem. 81, 1048-1050
  32. Childs, R. E., and Bardsley, W. G. (1975) Biochem. J. 145, 93-103 [Medline] [Order article via Infotrieve]
  33. Hiromi, K. (1979) Kinetics of Fast Enzyme Reactions, pp. 244-247, Halsted Press, New York
  34. Dunford, H. B., and Hewson, W. D. (1977) Biochemistry 16, 2949-2957 [Medline] [Order article via Infotrieve]
  35. Bernasconi, C. F. (1976) Relaxation Kinetics, pp. 31-34, Academic Press, New York
  36. Adediran, S. A., and Lambeir, A. (1989) Eur. J. Biochem. 186, 571-576 [Abstract]
  37. Newmyer, S. L., and Ortiz de Montellano, P. R. (1995) J. Biol. Chem. 270, 19430-19438 [Abstract/Free Full Text]
  38. Arnao, M. B., Acosta, M., Del Río, J. A., and García-Cánovas, F. (1990) Biochim. Biophys. Acta 1038, 85-89 [Medline] [Order article via Infotrieve]
  39. Arnao, M. B., García-Cánovas, F., and Acosta, M. (1996) Biochem. Mol. Biol. Int. 39, 97-107 [Medline] [Order article via Infotrieve]
  40. Takahama, U. (1993) Physiol. Plant. 89, 791-798 [CrossRef]
  41. Mehlhorn, H., Lelandais, M., Korth, H. G., and Foyer, C. H. (1996) FEBS Lett. 378, 203-206 [CrossRef][Medline] [Order article via Infotrieve]
  42. Levine, A., Tenhaken, R., Dixon, R., and Lamb, C. (1994) Cell 79, 583-593 [Medline] [Order article via Infotrieve]
  43. Cano, A., Artés, F., Arnao, M. B., Sánchez-Bravo, J., and Acosta, M. (1996) J. Plant Physiol. 147, 721-728
  44. Miller, V. P., DePillis, G. D., Ferrer, J. C., Mauk, A. G., and Ortiz de Montellano, P. R. (1992) J. Biol. Chem. 267, 8936-8942 [Abstract/Free Full Text]
  45. Gilfoyle, D. J., Rodriguez-Lopez, J. N., and Smith, A. T. (1996) Eur. J. Biochem. 236, 714-722 [Abstract]
  46. Garrido-del Solo, C., Garcia-Canovas, F., Havsteen, B. H., and Varon, R. (1993) Biochem. J. 294, 459-464 [Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.